"In vitro pharmacological profile of Compound A, a novel potent and selective LRRK2 inhibitor" Pascal Grondin, Arnaud François, Anne-Pascale Luzy, Cedric Vinson, Yann Lamotte, Petra Blom, Arnaud Le Tiran, Laurence Danober, Johannes Krupp, Jan Hoflack and Nicolas Ancellin Oncodesign SA, Institut de recherches Servier, Technologie Servier Biennial International LRRK2 meeting, Lille, France, June 28th to July 1st 2022
"In vivo PK/PD profile of Compound A, a brain penetrant, orally available potent and selective LRRK2 inhibitor, in rodent and non-rodent species" Arnaud François, Pascal Grondin, Guillaume Das Dores, Aurore Sors, Anne-Pascale Luzy, Cédric Vinson, Yann Lamotte, Petra Blom, Arnaud Le Tiran, Laurence Danober, Johannes Krupp, Jan Hoflackand Nicolas Ancellin Institut de recherches Servier, Oncodesign SA, Institut de Recherches Internationales Servier, Technologie Servier Biennial International LRRK2 meeting, Lille, France, June 28th to July 1st 2022
"Nanocyclix: next generation kinase therapeutics, A chemocentric approach for the discovery of selective kinase inhibitors" Petra Blom, Pascal Benderitter, Nicolas George, Marie-Hélène Fouchet, Alexis Denis, Jan Hoflack, Philippe Genne New Avenues in Kinase Drug Discovery: a Bright Future? Namur, Belgium – November 23, 2018
"Nanocyclix: next generation kinase therapeutics, A chemocentric approach for the discovery of selective kinase inhibitors" Petra BLOM, Pascal BENDERITTER, Nicolas GEORGE, Marie-Hélène FOUCHET, Alexis DENIS and Jan HOFLACK XXV EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC 2018), Ljubljana, Slovenia - September 2-6, 2018
"Application of the Nanocyclix® technology to identify clinically relevant PET tracers. The first [18F]-Nanocyclix® TKI-PET radiotracer targeting activated EGFR positive lung tumors P. Blom, C. Mothes, G. Viot, C. Vala, P. Provent, J. Vercouillie, C. Berthet, J. Hoflack EFMC-ASMC’17 – EFMC International symposium on advances in synthetic and medicinal chemistry, Vienna, Austria, August 27-31, 2017
"Opening the gate to novel ion channel modulators and innovative anti-arrhythmics" Petra Blom, Titus Kaletta, Thomas Brown, Thierry Bogaert and Dirk Leysen Personalized Medicine: New Opportunities for Drug Discovery, Antwerp, Belgium, November 10, 2006
"Innovative technologies for ion channel HTS, leading to novel in vivo active anti-arrhythmics Petra Blom, Titus Kaletta, Geert Plaetinck, Richard Zwaal, Andreas Köpke, Thomas Brown, Eric Fourmaintraux, Jan De Kerpel, Thierry Bogaert and Dirk Leysen 15th Noordwijkerhout-Camerino symposium, Noordwijkerhout, the Netherlands, May 8-13, 2005
